IX Biopharma

CSE Global Jumps 6% Heading Into the Close | Daily Pulse | 🦖

🔍 The Angle

CSE Global is up almost 6% on a day when the index barely moves, and IX Biopharma is swinging close to 8% on tiny volume. Underneath a quiet tape, we have real money shifting in CSE, YZJ, UMS, while names like HS Optimus and Prospera Global print wild percentages at fractions of a cent that can mislead anyone watching only the gainers list. The tension I am watching is simple, which of today’s big moves are genuine signals for your income, and which are just statistical noise.

💰 What It Means For You

If you rely on CPF, SRS, or REIT dividends, a 6% spike in a name you hold can feel like a win, but without checking volume, price level, and the underlying business news, it might be as empty as a one trade move at S$0.01. Today is a textbook reminder that big percentage moves at penny levels rarely clear any sensible 4.7% yield hurdle or 3.2% forensic floor, they just make the screen light up. I want you to separate the CSE or CICT type moves, tied to real strategic reviews and Paragon capex, from the HS Optimus type moves, where the number is loud but the story is thin.

📺 YouTube:  https://youtu.be/aZVUpayZ4q4

📩 Substack: https://investingiguana.com/p/cse-global-jumps-6-heading-into-the

iX Biopharma has announced a non-binding term sheet with Orion Specialty Labs to form a joint venture in the U.S. iX will own 75 percent of the venture while Orion takes 25 percent and covers the capital costs. The goal is to use Orion’s existing FDA-licensed facilities to bring iX’s WaferiX technology to market faster, with pilot production aimed for the second half of 2026. The deal is not yet final, and there’s no expected immediate financial impact for iX.���������